Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
NHS Framework Agreement for the supply of Direct Oral Anticoagulants (DOACs) for the NHS in England. Also known as Novel Oral Anticoagulants (NOACs).
Period of Framework: 01/01/2022 - 31/03/2024 with an option to extend (at the Authority's discretion) for a further period (or periods) up to a total of 12 months (i.e. total possible framework duration of 39 months)
| Supplier | Identifier | Award Value | Cross-References |
|---|---|---|---|
| Bayer Ltd | 16954143 | ~£3,185,000,000 estimated from lot values | - |
| Bristol Myers Squibb | 02487574 | ~£3,185,000,000 estimated from lot values | - |
| Daiichi Sankyo UK Ltd | 01998736 | ~£3,185,000,000 estimated from lot values | LOBBYIST WA Communications Ltd (2 quarters) Hanover Communications International Limited (1 quarter) FORMER MP Sir Kevin Barron— Employment and earnings (former) |
Government spending data: These suppliers have received £36,151,969 in 875 payments (over £25k) from Guy's and St Thomas' NHS FT, Plymouth Hospitals NHS Trust, Royal Cornwall Hospitals NHS Trust, Maidstone and Tunbridge Wells NHS Trust, United Lincolnshire Hospitals NHS Trust and 8 more public bodies (2020-01-06 to 2026-03-31).